Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

Reuters11-20

Nov 13 (Reuters) - Cartesian Therapeutics Inc ::
*CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INTO MYOSITIS
*CARTESIAN - 100% LLDAS RESPONSE RATE OBSERVED IN PATIENTS WITH SLE WHO GOT DESCARTES-08 IN PHASE 2 OPEN-LABEL TRIAL REACHING MONTH 3 FOLLOW-UP
*CARTESIAN THERAPEUTICS INC - CARTESIAN PLANS TO PAUSE FURTHER DEVELOPMENT OF DESCARTES-08 IN SLE
*CARTESIAN THERAPEUTICS INC - PLANS TO PAUSE DEVELOPMENT OF DESCARTES-15 TO PRIORITIZE OPPORTUNITIES FOR DESCARTES-08 IN MG AND MYOSITIS
*CARTESIAN: MYOSITIS SEAMLESS ADAPTIVE CLINICAL TRIAL DESIGN PROVIDES POTENTIAL OPPORTUNITY FOR SINGLE PIVOTAL TRIAL EXPECTED TO COMMENCE IN 1H26

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 13-NOV-202521:05:04.977 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584229829?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 01:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584229829","market":"fut","top_or_hot":-1,"title":"Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis","media":"Reuters","content":"<html><body>Nov 13 (Reuters) - <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> Inc <rnac.o>::<br/>*CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INTO MYOSITIS<br/>*CARTESIAN - 100% LLDAS RESPONSE RATE OBSERVED IN PATIENTS WITH SLE WHO GOT DESCARTES-08 IN PHASE 2 OPEN-LABEL TRIAL REACHING MONTH 3 FOLLOW-UP<br/>*CARTESIAN THERAPEUTICS INC - CARTESIAN PLANS TO PAUSE FURTHER DEVELOPMENT OF DESCARTES-08 IN SLE<br/>*CARTESIAN THERAPEUTICS INC - PLANS TO PAUSE DEVELOPMENT OF DESCARTES-15 TO PRIORITIZE OPPORTUNITIES FOR DESCARTES-08 IN MG AND MYOSITIS<br/>*CARTESIAN: MYOSITIS SEAMLESS ADAPTIVE CLINICAL TRIAL DESIGN PROVIDES POTENTIAL OPPORTUNITY FOR SINGLE PIVOTAL TRIAL EXPECTED TO COMMENCE IN 1H26<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 13-NOV-202521:05:04.977 GMT</rnac.o></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 01:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Nov 13 (Reuters) - <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> Inc <rnac.o>::<br/>*CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INTO MYOSITIS<br/>*CARTESIAN - 100% LLDAS RESPONSE RATE OBSERVED IN PATIENTS WITH SLE WHO GOT DESCARTES-08 IN PHASE 2 OPEN-LABEL TRIAL REACHING MONTH 3 FOLLOW-UP<br/>*CARTESIAN THERAPEUTICS INC - CARTESIAN PLANS TO PAUSE FURTHER DEVELOPMENT OF DESCARTES-08 IN SLE<br/>*CARTESIAN THERAPEUTICS INC - PLANS TO PAUSE DEVELOPMENT OF DESCARTES-15 TO PRIORITIZE OPPORTUNITIES FOR DESCARTES-08 IN MG AND MYOSITIS<br/>*CARTESIAN: MYOSITIS SEAMLESS ADAPTIVE CLINICAL TRIAL DESIGN PROVIDES POTENTIAL OPPORTUNITY FOR SINGLE PIVOTAL TRIAL EXPECTED TO COMMENCE IN 1H26<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 13-NOV-202521:05:04.977 GMT</rnac.o></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2K1SXx:1","article_id":"2584229829","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584229829","pubTimestamp":1763574060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nov 13 (Reuters) - Cartesian Therapeutics Inc ::*CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RNAC":"Cartesian Therapeutics"},"translate_title":"Cartesian Therapeutics宣布Descartes-08在SLE患者中的2期试验中出现强烈疗效信号，并将临床开发扩展至肌炎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAC":0.9},"content_text":"Nov 13 (Reuters) - Cartesian Therapeutics Inc ::*CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INTO MYOSITIS*CARTESIAN - 100% LLDAS RESPONSE RATE OBSERVED IN PATIENTS WITH SLE WHO GOT DESCARTES-08 IN PHASE 2 OPEN-LABEL TRIAL REACHING MONTH 3 FOLLOW-UP*CARTESIAN THERAPEUTICS INC - CARTESIAN PLANS TO PAUSE FURTHER DEVELOPMENT OF DESCARTES-08 IN SLE*CARTESIAN THERAPEUTICS INC - PLANS TO PAUSE DEVELOPMENT OF DESCARTES-15 TO PRIORITIZE OPPORTUNITIES FOR DESCARTES-08 IN MG AND MYOSITIS*CARTESIAN: MYOSITIS SEAMLESS ADAPTIVE CLINICAL TRIAL DESIGN PROVIDES POTENTIAL OPPORTUNITY FOR SINGLE PIVOTAL TRIAL EXPECTED TO COMMENCE IN 1H26  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202521:05:04.977 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584229829","isCrawlerRequest":true}